Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

301-306 of 306 trials

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPsychiatry

Graves' Disease: Rilzabrutinib Study

We are investigating whether rilzabrutinib can help reduce thyroid activity in adults with Graves' disease. The study also aims to evaluate the safety of this new treatment.

Graves' Disease3-6 monthsEfficacy phase (II)11-15 visits No Placebo Investigational Medicines Partially RemoteEndocrinologyInternal Medicine

Tulisokibart for Ankylosing Spondylitis

We are studying a new medication, tulisokibart, to see if it helps people with ankylosing spondylitis feel better compared to a placebo. The trial will assess improvements in pain, function, and overall quality of life.

Ankylosing Spondylitis>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational MedicinesRheumatology

Zelenectide Pevedotin for Advanced Non-small Cell Lung Cancer

We are studying a new treatment for patients with advanced or metastatic non-small cell lung cancer that has NECTIN4 amplification. The goal is to see how well it works and how safe it is for those who have already been treated.

Advanced Non-small Cell Lung Cancer1-2 yearsEfficacy phase (II)11-15 visits No Placebo Investigational MedicinesOncology

Vormatrigine for Adults with Epilepsy

We are studying the safety and tolerability of vormatrigine in adults with focal or generalized tonic-clonic seizures. We also aim to explore its effects on seizure frequency and overall patient experience.

Focal Epilepsy and Tonic-Clonic EpilepsyConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurology

TAR-0520 Gel for Preventing Nerve Damage in Breast Cancer Patients

We are studying whether TAR-0520 Gel can safely prevent nerve damage and nail changes in patients receiving taxane chemotherapy for breast cancer.